Comment on “Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study”

Diabetes & Metabolic Syndrome Clinical Research & Reviews 2026

View at publisher

Authors: S Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai

DOI: 10.1016/j.dsx.2026.103418

Cited by: 1

References: 3

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Lipoproteins and Cardiovascular Health

References 3